Health · Pharma & Biotech · 3 hrs ago
Lilly says retatrutide outperformed Ozempic in diabetes study
Eli Lilly says its investigational drug retatrutide outperformed Ozempic in a head-to-head study involving people with diabetes.
Ozempic is made by Novo Nordisk, and the study compared the two drugs over 80 weeks.
At the highest dose, retatrutide lowered A1c, a measure of blood sugar, by 2.2 percentage points, compared with 1.8 points for Ozempic.
People on the highest dose of retatrutide lost 20.9% of their weight, while those taking Ozempic lost 9.4%.
The results were calculated only for participants who stayed on treatment, not for everyone who began the study.
The findings strengthen retatrutide’s competitive position, but the drug is still investigational.
The information provided does not say what happens next with the study or the drug.
Eli Lilly said its investigational drug retatrutide outperformed Novo Nordisk’s Ozempic in a head-to-head diabetes study.
After 80 weeks, participants on the highest dose of retatrutide had a 2.2 percentage-point reduction in A1c, compared with 1.8 percentage points for Ozempic.
Participants on the highest dose of retatrutide lost 20.9% of their weight, compared with 9.4% for Ozempic.
The results were based on analyses of participants who stayed on treatment, not all participants.
- Who
- Eli Lilly reported the results; the study compared retatrutide with Novo Nordisk’s Ozempic in people with diabetes.
- What
- Lilly said retatrutide lowered blood sugar and weight more than Ozempic in a head-to-head study.
- When
- Lilly announced the results on Wednesday, October 28, 2026.
- Where
- Not stated.
- Why
- The results further boosted the competitive profile of Lilly’s medicine.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Highest-dose retatrutide A1c reduction
- 2.2 percentage points after 80 weeks
- Ozempic A1c reduction
- 1.8 percentage points after 80 weeks
- Highest-dose retatrutide weight loss
- 20.9%
- Ozempic weight loss
- 9.4%
- Analysis population
- Participants who stayed on treatment